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Abstract: A number of natural products from marine sponges, such as cyclodepsipeptides, 
have been identified. The structural characteristics of this family of cyclic peptides include 
various unusual amino acid residues and unique N-terminal polyketide-derived moieties. 
Papuamides are representatives of a class of marine sponge derived cyclic depsipeptides, 
including callipeltin A, celebesides A and B, homophymine A, mirabamides, 
microspinosamide, neamphamide A and theopapuamides. They are thought to have 
cytoprotective activity against HIV-1 in vitro by inhibiting viral entry. Jasplakinolide, a 
representative member of marine sponge-derived cyclodepsipeptides that include 
arenastatin A, geodiamolides, homophymines, spongidepsin and theopapuamides, is a 
potent inducer of actin polymerization in vitro. Although actin dynamics is essential for 
tumor metasasis, no actin targeting drugs have been used in clinical trials due to their 
severe cytotoxicity. Nonetheless, the actin cytoskeleton remains a potential target for anti-
cancer drug development. These features imply the use of cyclodepsipeptides as molecular 
models in drug research. 
Keywords:  cyclodepsipeptides; papuamides; jasplakinolide; actin polymerisation; HIV 
entry inhibitors 
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1. Introduction  
Cyclodepsipeptidic secondary metabolites produced by marine and terrestrial organisms have 
unique structures comprised of unusual amino acids and non-amino acid moieties. The novel structural 
features and the wide spectrum of biological activities of these peptidic metabolites have generated 
considerable interest. However, it is rather difficult to isolate sufficient quantities of these metabolites 
for pharmacological and toxicological testing. Therefore, structural determination and total syntheses 
of these natural compounds are required. Progress towards the synthesis and study of potential drugs of 
different chemical structures, isolated from various marine organisms, has been extensively reviewed 
[1–22]. This review will focus on cyclodepsipeptides derived from marine sponges. A series of potent 
HIV inhibitory cyclic depsipeptides have been described from a number of marine sponges, as well as 
numerous compounds, which exhibit potent cytotoxic properties in vitro, and this will be discussed in 
this review. 
The HIV replication cycle offers multiple targets for chemotherapeutic intervention, including the 
viral exterior envelope glycoprotein gp120, viral co-receptors CXCR4 and CCR5, transmembrane 
glycoprotein gp41, integrase, reverse transcriptase and protease. Most currently approved anti-HIV 
drugs belong to nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse 
transcriptase inhibitors or protease inhibitors. Highly active antiretroviral therapy, which combines 
several drugs, has dramatically improved patient lives. However, adverse side effects, long-term 
toxicity and drug resistance limit their therapeutic effect. In addition to the above-mentioned drugs, 
compounds that target viral entry and virus-cell fusion have great potential for the treatment of HIV 
infections. The sponge-derived cylodepsipeptides papuamide and mirabamides have been shown to 
inhibit HIV entry into cells [23,24]. HIV entry into host cells is a multi-step process that remains to be 
fully elucidated. The proteins involved in the entry process have become attractive targets for drug 
design. Natural probes such as depsipeptides, which target viral entry, could provide valuable 
information for computer-aided drug design. In this context, recent achievements in the treatment of 
HIV infection and the application of computational methods for current drug design was recently 
reviewed [25]. 
Most currently used anticancer drugs, in particular those that are cytotoxic, affect the defining 
characteristic of cancer cells, namely the process of cell division. Thus, these drugs are 
antiproliferative, but they have no specific inhibitory effect on invasiveness, the loss of differentiation 
or the tendency to metastasize. However, a number of recently developed drugs, such as receptor 
tyrosine kinase inhibitors and monoclonal antibodies, affect specific targets associated with tumor cells 
or endothelial cells. Cyclodepsipeptides are currently under evaluation in clinical trials in patients with 
cancer refractory to standard therapy. Kahalalide F and aplidin (plitidepsin) have shown promising 
results in phase I and II clinical trials, especially when administered in combination with other 
cytotoxic agents. Kahalalide F was isolated from the mollusks Elysia rufescens and Spisula polynyma, 
and from the green alga Bryopsis sp. [26]. In phase I clinical trials, kahalalide F provided a benefit to 
patients with advanced androgen-refractory prostate cancer and other advanced tumors [27,28]. 
Aplidin (plitidepsin) is a cyclodepsipeptide originally isolated from the Mediterranean tunicate 
Aplidium albicans, and has been demonstrated to have strong anticancer activity against a variety of 
cultured human cancer cells and in tumor-bearing nude mice. Phase I and II clinical trials of aplidin Mar. Drugs 2010, 8                
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have yielded promising results in cancer patients [29–38]. These examples show that 
cyclodepsipeptides may be of interest in the development of new agents and combination therapies 
with different mechanisms of action. 
2. Compounds with Anti-HIV Activity 
2.1. Structural characteristics  
The antiviral cyclic depsipeptides neamphamide A, callipeltins, papuamides and mirabamides have 
been isolated from various marine sponges. Papuamide A’s activity is representative of the group of 
marine depsipeptides shown to inhibit HIV induced cytopathicity. Papuamide A (Figure 1) shares 
many chemical features with this group including an aliphatic tail, depsipeptide cyclisation, a   
3,4-dimethylglutamine residue and an available tyrosine hydroxyl group, which is glycosylated in 
mirabamides. The distinguishing structural characteristics of this family of cyclic peptides include a 
preponderance of unusual amino acid residues and unique N-terminal polyketide-derived moieties 
(Table 1). For instance, the atypical amino acid residues 3,4-dimethyl-L-glutamine and   
β-methoxytyrosine are common to all of the above mentioned sponge-derived cyclodepsipeptides, but 
to date have not been described elsewhere. As a result, syntheses of structural subunits such as   
3,4-dimethyl-L-glutamine [39], 4-amido-7-guanidino-2,3-dihydroxyheptanoic acid [40] and   
3-hydroxy-2,4,6-trimethylheptanoic acid [41] have provided the essential building blocks for use in 
total synthesis of the peptides, and have also helped to define the absolute stereochemistry of several 
key chiral centers. However, synthetic efforts to prepare intact natural products have been hampered 
by unresolved questions concerning the stereochemistry of β-methoxytyrosine residues, which occur 
throughout this family of peptides. While stereoselective syntheses of all four diastereomers of   
β-methoxytyrosine have been reported [42,43], the absolute stereochemistry of this residue in natural 
peptides was not established. Decomposition of β-methoxytyrosine during acid hydrolysis of the 
parent peptide has prevented the successful application of standard techniques such as Marfey’s 
analysis. Oku et al. [44] described the complete stereochemical assignment of neamphamide A and a 
general method for determining the absolute stereochemistry of β-methoxytyrosine residues in other 
peptides. This technique was also used to define the stereochemistry of the same residue in papuamide 
B, which was determined as (R)-β-methoxy-D-tyrosine. So far, such efforts have led to the successful 
establishment of the stereochemistry of some stereogenic centers within this class of 
cyclodepsipeptides [1,5,45–47]. However, none of these molecules had been assembled until Xie et al. 
[48] reported their synthetic strategy towards papuamide B. This features stereoselective assembly of 
its dienoic acid fragment and an efficient elaboration of the (2S,3S,4R)-3,4-dimethylglutamine residue 
through a 3,4,5-trisubstituted δ-valerolactone. This latter approach may benefit total synthesis of other 
anti-HIV cyclic depsipeptides such as callipeltin A and neamphamide A. The development of synthetic 
strategies will support large-scale syntheses of related natural products and their analogs, which would 
prompt structure-activity relationship studies.  Mar. Drugs 2010, 8                
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Figure 1. Structure of papuamide A. 
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Table 1. Structural characteristics of sponge-derived cyclodepsipeptides. 
Cyclo-Depsipeptide Marine  Sponge  Uncommon  Residues 
Amino acids  Polyketide moieties  Ref. 
Callipeltin A  Callipelta sp.  AGDHA 
3,4-DiMeGln 
β-OMeTyr 
 [40] 
[43] 
[45] 
[49] 
Celebesides   Siliquariaspongia mirabilis  ACPA  
3,4-DiMeGln 
3-CThr  
pSer (Cel. A, B) 
DDTD 
HTMOA 
[50] 
Homophymine A  Homophymia sp  ADHA  
AHDMHA  
3,4-DiMeGln 
ThrOMe  
HTMOA [51] 
Microspinosamide Sidonops  microspinosa  N-MeGln 
HBPA 
 [52] 
Mirabamides   Siliquariaspongia mirabilis  Dab (except M. B) 
3,4-DiMeGln 
β-OMeTyrRP 
ClHPr 
DHTDA [24] 
Neamphamide A  Neamphius huxleyi  AGDHA  
3,4-DiMeGln 
N-MeGln 
β-OMeTyr 
HTMHA [44] 
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Table 1. Cont. 
Papuamides   Theonella mirabilis  
and 
Theonella swinhoei 
Dab  
3,4-DiMeGln  
hPro  
β-OMeTyr 
3-OHLeu  
DHTDA [48] 
[53] 
[54] 
Theopapuamides  
 
 
 
Geodia barretti 
and 
Siliquariaspongia mirabilis 
ACPA  
AMDHA (Th. B) 
AMTHA (Th. A) 
3,4-DiMeGln  
N-MeGln 
hiLeu (Th. C) 
HTMOA [55] 
Abbreviations: 
ACPA     3-acetamido-2-aminopropanoic acid 
ADHA   4-amino-2,3-dihydroxy-1,7-heptanoic  acid 
AGDHA 4-amino-7-guanidino-2,3-dihydroxyheptanoic  acid 
AHDMHA 2-amino-3-hydroxy-4,5-dimethylhexanoic  acid 
AMDHA   4-amino-2,3-dihydroxy-5-methylhexanoic acid 
AMTHA   4-amino-2,3,5-trihydroxy-5-methylhexanoic acid 
ClHPr   4-chlorohomoproline 
3-CThr    3-carbamoyl threonine 
Dab   2,3-diaminobutanoic  acid 
DDTD     7,9-dihydroxy-8,10-dimethyltrideca-2,4-dienoic acid 
DHTDA   2,3-dihydroxy-2,6,8-trimethyldeca-4,6-dienoic acid 
3,4-DiMeGln   3,4-dimethyl-L-glutamine 
hiLeu     homoisoleucine 
hPro   homoproline 
HBPA   β-hydroxy-p-bromophenylalanine  
HTMOA   3-hydroxy-2,4,6-trimethyloctanoic acid 
HTMHA 3-hydroxy-2,4,6-trimethylheptanoic  acid 
N-MeGln  N-Methylglutamin 
β-OMeTyr  β-methoxytyrosine 
β-OMeTyrRP  β-methoxytyrosine 4’-O-α-L-rhamnopyranoside 
3-OHLeu 3-hydroxyleucine 
pSer   phosphoserine 
ThrOMe   O-methyltreonine 
2.2. Mode of action  
Because viruses share many metabolic processes with the host cell, it is difficult to find drugs that 
are selective for the viral pathogen. However, there are some enzymes that are virus specific and these 
are potential drug targets. Most currently available antiviral agents are only effective during viral 
replication. The HIV virus uses the CD4 co-receptor and the chemokine receptor CCR5 or CXCR4 as 
binding sites. 
Transcription occurs when the T cell is activated. Transcription of both the host cell DNA and the 
provirus is initiated by the transcription factor NF-κB. The action of the viral protease involves the Mar. Drugs 2010, 8                
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cleavage of polypeptides into structural proteins and enzymes for the new virion. Currently, available 
drugs inhibit nucleotide or non-nucleotide reverse transcriptase or protease. Reverse transcriptase 
makes double-stranded DNA copies of viral RNA, and protease acts on immature virions after 
budding. The combination of these two classes of anti-HIV drugs has improved dramatically the 
prognosis of HIV/AIDS patients. However, the regimen is complex and has many unwanted effects. 
For example, the virus is not eradicated, but rather remains latent in memory T cells, and can become 
reactivated if the drugs are stopped. Furthermore, the virus has a high mutation rate, which could be a 
problem for future HIV treatments. Thus, there is need to find new and additional methods to treat 
HIV. The sites of action for potential new drugs include binding of the virion, entry of the virion, 
uncoating of virion, translocation of viral complementary DNA into the nucleus, integration of viral 
cDNA into host cell DNA, inhibition of the gene coding the HIV core protein, and inhibition of 
budding. Agents that inhibit viral entry are particularly sought after because they can prevent infection. 
Papuamides are representatives of a class of marine derived cyclic depsipeptides, including 
callipeltin A, celebesides A and B, homophymine A, mirabamides, microspinosamide, neamphamide 
A and theopapuamides. They are all reported to have cytoprotective activity against HIV-1 in vitro 
(Table 2).  
Table 2. Anti-HIV activity of cyclodepsipeptides. 
Cyclo-
Depsipeptide 
Assay Anti-HIV  Activity 
(IC50) 
Cytotoxicity (TC50) Ref. 
Callipeltin A  MTT cell viability on CEM4 lymphocytic cell lines infected with 
HIV-1 (Lai strain, X4 tropic) 
0.01 μg/mL 
 
0.29 μg/mL [49] 
Celebesides  single-round HIV-1 infectivity assay against viruses pseudo-typed 
with HIV-1 SF162 Envelope 
A: 1.9 µg/mL 
B: >50 µg/mL 
 [50] 
Homophymine A  production of HIV-1 virus (III B strain) measured by quantification 
of reverse transcriptase activity associated with the virus particles in 
PBMC cell lines  
75 nM 
 
1.19 μM [51] 
Microspinosamide  XTT-based cell viability assay in HIV-1 infected CEM-SS target 
cells 
0.2 µg/mL 
 
3.0 µg/mL  [52] 
Mirabamides A-D  HIV-1 neutralization assays:  
HXB2 (T-cell-tropic) and SF162 (macrophage-tropic) viral strains;  
TZM-bl host cells (expressing CXCR4, CCR5, and CD4) 
 
 
 
 
 
 
HIV-1 envelope-mediated cell fusion assay 
HXB2: 
A: 140 nM 
B: >50 µM 
C: 140 nM 
D: 190 nM 
SF162: 
A: 400 nM 
C, D: 1 µM 
 
A: 41 nM 
C, D: low µM range 
 [24] 
 
 
 
 
 
 
 
Neamphamide A  XTT-based cell viability assay: human T-cell line CEM-SS infected 
with HIV-1RF 
28 nM 
 
260 nM  [44] 
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Table 2. Cont. 
Papuamide A  HIV-1 envelope-mediated cell fusion assay 
 
MTT cell viability test 
 
Virion based fusion assay:  
co-transfection of pMM310 (plasmid encoding β-lactamase),  
pAdV Antage (vector), pNL4-3 (X4 tropic proviral DNA) or 
pNL(AD8) (R5 tropic proviral DNA) into 293FT cells; 
HeLaT4 or TZM-bl host cells  
 
Pseudo-type virus assay: pDHIV-3 plus envelope glycoprotein 
plasmids transfected to 293FT cells; 
Target cells: CEM-SS or CEM.NKR-CCR5 cells 
 
tetrazolium-based assay 
CEM-SS T-cells 
73 nM 
 
71 nM 
 
114 nM 
 
 
 
 
 
178 nM 
 
 
 
3.6 ng/mL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 ng/mL 
[24] 
 
[23] 
 
[23] 
 
 
 
 
 
[23] 
 
 
 
[53] 
Theopapuamide B  single-round HIV-1 infectivity assay against viruses pseudo-typed 
with HIV-1 SF162 Envelope 
0.8 µg/mL    [50] 
Abbreviations: 
IC50: half-maximal concentration for cytoprotective activity against HIV-infection 
TC50: concentration for 50% reduction in cell viability (half-maximal concentration for cytotoxic response) 
IC50 and TC50 values were not calculated by use of the same assay and exposure time. 
“A”, “B”, “C” and “D” in the column “anti HIV activity” correspond to celebesides A and B, and mirabamides A, B, C and D in the 
respective rows. 
Andjelic  et al. [23] recently determined that anti-HIV action of papuamide A occurs through 
inhibition of virus entry, which is a three-stage process. At first, the virus attaches to the HIV gp120 
recognition particle and binds to the host cell receptor CD4 [56,57], which initiates conformational 
changes within gp120 to expose a new epitope. This epitope interacts with the cellular chemokine  
co-receptors CCR5 or CXCR4 [58]. Thereafter, gp120 and gp41 undergo further conformational 
changes to expose the extracellular region of gp41 [59], in which the N-terminal region contains a 
fusion peptide that inserts itself into the cell membrane [60]. Finally, two helical regions of gp41 fold 
upon each other, bringing the viral and cellular membranes into close proximity. This structural 
rearrangement causes lipid mixing and fusion of the two membranes, so that the viral core can enter 
the host cell [61–73]. 
For papuamide A, the inhibition of virus entry is not specific to R5 or X4 tropic virus [23]. 
Papuamide A’s ability to inhibit both the X4 and R5 tropic virus was similar to the mirabamides, 
which were shown to inhibit fusion [24]. Furthermore, papuamide A inhibition does not target the key 
proteins involved in the viral entry process such as binding to CD4 or HIV gp120. Instead papuamide 
A works through direct interaction with the virus, and its virucidal activity appears to be independent 
of the type of envelope glycoprotein expressed, because papuamide A can inhibit HIV pseudo-type 
viruses expressing envelope glycoproteins from vesicular stomatitis virus or amphotropic murine Mar. Drugs 2010, 8                
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leukemia virus. This indicates that the mechanism of viral entry inhibition is not HIV-1 envelope 
glycoprotein specific. Time delayed addition studies with pseudo-typed viruses have shown that 
papuamide A inhibits viral infection only at the initial stage of the viral life cycle. Additionally, 
pretreatment studies revealed that the virus, and not the cell, is the target of papuamide A’s action [23]. 
At similar concentrations to papuamide A, it was demonstrated that papuamides B also inhibits viral 
entry. Phosphatidylserine, which is a phospholipid present on the viral membrane, has been proposed 
to be the target of papuamide B.  
A proposed model for the mechanism of virucidal activity for these compounds is based on the 
membrane targeting mechanism proposed for the sterol-dependent antifungal antibiotic bacillomycin 
[64]. In this model, the lipopeptide has an aliphatic tail, which inserts itself into the fungal membrane. 
The interaction is then stabilized through tyrosine binding to sterol present in the fungal membrane. 
Cholesterol is a major component of the HIV viral membrane due to budding from cellular membrane 
micro-domains rich in cholesterol and sphingolipids [65,66]. 
To determine the effects of mirabamides on HIV-1 infection, these compounds were tested against 
two viral strains in HIV-1 neutralization assays. In addition, mirabamides A-D were tested in an HIV-1 
envelope-mediated cell fusion assay to determine whether they act during early steps of infection, 
namely viral entry (Table 2). Mirabamides A, C, and D potently inhibited HXB2 infection of TZM-bl 
host cells, while mirabamide B was significantly less active. Relative to HXB2, mirabamides A, C and 
D showed slightly reduced potency toward SF162, and as with HXB2, mirabamide B only weakly 
inhibited SF162. Mirabamide A, C and D inhibited HIV-1 in neutralization and fusion assays 
indicating that these cyclodepsipeptides also can act during early stages of HIV-1 entry [24]. 
In comparison to papuamide A, mirabamides A-D inhibited HIV-1 envelope-mediated fusion with 
activities comparable to those observed in neutralization assays. Mirabamide A and papuamide A were 
the most potent inhibitors in the fusion assay (Table 2), while mirabamides C and D inhibited fusion at 
low micromolar concentrations. Similar to papuamides A and B, mirabamides also exhibited potent 
anti-HIV activity toward multiple strains of HIV. Furthermore, the results demonstrated that this class 
of cyclodepsipeptides acts during HIV-1 membrane fusion, presumably through interaction with   
HIV-1 envelope glycoproteins [24]. 
Although recent research has been conducted on the synthesis, biological activity and mode of 
action of cyclodepsipeptides from marine sponges, the molecular targets that mediate the effects of 
these natural compounds on viral entry have yet to be identified. 
2.3. Structure-activity relationship  
Common attributes of papuamide A and other anti-HIV active depsipeptides include a tyrosine that 
can interact with cholesterol and a hydrophobic tail that can insert into the viral membrane, resulting in 
a virucidal effect. Cooperative binding to phosphatidylserine might preferentially target papuamide A 
to the viral membrane over the cellular membrane [23]. Similar to papuamide A, celebeside A and B 
also can inhibit HIV-1 entry (Table 2), while celebeside C, which lacks the phosphoserine residue, is 
inactive. These data further support the assumption that anti-HIV activity correlates with the presence 
of phosphoserine [50]. However, while papuamide A selectively binds to phosphatidylserine, binding 
to phosphatidylserine alone is not sufficient to block viral entry [23].  Mar. Drugs 2010, 8                
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Papuamide C and D inhibit HIV entry as well, although less potently than A and B. This suggests 
that the free amino group of the 2,3-diaminobutanoic acid residue of papuamides A and B is not 
required, although it may contribute to virucidal activity of these compounds [23]. Similarly, 
mirabamide B is less potent than mirabamides A, C, and D in both neutralization and fusion assays. 
Mirabamide B is the only of the four cyclodepsipeptides to contain a 2,3-dehydro-2-aminobutanoic 
acid residue in place of the 2,3-diaminobutanoic acid residue found in mirabamide A, C and D, as well 
as papuamides A and B. Thus, this residue seems to be important for the anti-HIV activity in this class 
of cyclodepsipeptides [24]. 
Mirabamide A, which contains the rhamnosylated β-methyltyrosine residue, was observed to be the 
most potent of the four mirabamides. Ratnayake et al. [55] suggested that the β-methyltyrosine residue 
is critical for the anti-HIV activity of theopapuamide. However, data obtained with mirabamides 
suggest that the β-methyltyrosine residue alone is not essential for anti-HIV activity [24]. Rather, these 
results may indicate that β-methyltyrosine residues bearing a substitution at the 4′ position can be 
tolerated with no deleterious effects on antiviral activity and the presence of a free 4′ hydroxyl on the 
tyrosine unit is not essential. One hypothesis that is consistent with results reported for mirabamide A 
and papuamide A, which both contain a β-methyltyrosine, is that this residue imparts a specific 
conformation required for binding to target protein/s involved in HIV-1 entry [24]. Theopapuamide, 
which lacks a β-methyltyrosine residue, was reported to be inactive [24], but later studies 
demonstrated that theopapuamide B is active in the neutralization assay (Table 2) [50]. Further 
evidence is given by results obtained with homophymine A (Table 2). The antiviral activity found in 
homophymine A, in which the β-methoxytyrosine is replaced by an O-methyl threonine, ruled out the 
hypothesis that β-methoxytyrosine is essential for antiviral activity [51].  
3. Compounds with Anti-tumor Activity  
Malignant cancer cells utilize their intrinsic migratory ability to invade adjacent tissues and the 
vasculature, and ultimately to metastasize. The spread of cancer cells to distant sites in the body is the 
major cause of death in cancer patient. Therefore, a big challenge in cancer therapy is to inhibit the 
spread of tumor cells from primary tumor sites to other organs. Various compounds exert anti-
migratory effects, and some of them have also been shown to prevent tumor metastasis. Most of their 
migration-inhibiting effects are based either on interference with tumor adhesion to extracellular 
matrix components or on the reduction of tumor cell-associated protease activity.  
Cell migration occurs through membrane protrusion, adhesion to the extracellular matrix, cell body 
translocation, and tail retraction. All of these processes imply the role of actin, a key cytoskeletal 
element that is controlled by proteins both inside and outside of the cell. Disruption of cytoskeleton 
elements such as microtubules and microfilaments has been shown to interfere with the invasiveness 
and adhesion of tumor cells during the initial phases of metastasis formation. The actin cytoskeleton 
constitutes a potential target of interest for anti-cancer drug development [67].  Mar. Drugs 2010, 8                
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3.1. Structural features  
Jasplakinolide, also known as jaspamide, is a cyclic peptide with a 15-carbon macrocyclic ring 
containing three amino acid residues, L-alanine,  N-methyl-2-bromotryptophan, and β-tyrosine  
(Figure 2). From a structural point of view, jasplakinolide is a representative member of the 
cyclodepsipeptide family with an L-Ala-D-N-Me-2-BrTrp-L-β-Tyr tripeptide fragment, which is linked 
to a ω-hydroxyacid of polyketide origin, containing four methyl groups, located at 1–3 distance, as 
well as a trisubstituted double bond [68]. The importance of the D-BrTrp-L-β-Tyr segment in the 
backbone and the aromatic electrons of the β-tyrosine residue during binding of jasplakinolide to other 
positively charged species such as metal ions and positively charged amino acid residues of proteins 
has been demonstrated. Such binding could cause conformational changes in both jasplakinolide and 
target proteins and affect their properties [69]. 
Figure 2. Structure of jasplakinolide.  
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Callipeltin A is a macrocyclic lactone containing four amino acids in the L configuration, alanine, 
leucine, threonine (two residues); one (arginine) in the D configuration; two N-methyl amino acids,  
N-methyl alanine and N-methyl glutamine; a methoxy tyrosine, a 3,4-dimethyl-L-glutamine; and a  
4-amino-7-guanidino-2,3-dihydroxypentanoic acid (AGDHE), formally derived from L-arginine [70].  
In addition to their antiviral activity, homophymines [71] and theopapuamide [55] exhibit 
cytotoxicity against various tumor cell lines. All of these cyclic depsipeptides contain   
β-methoxytyrosine. Therefore, the desmethoxy analog of callipeltin B was synthesized to evaluate the 
role of its β-methoxytyrosine residue. It was speculated that cytotoxicity results from the elimination 
of methanol from β-methoxytyrosine to form a reactive quinone methide intermediate. However, in an 
MTT assay with HeLa cells, no difference in cytotoxic activity was found between callipeltin B and its 
desmethoxy analog, suggesting that this intermediate is unlikely to be the principal source of 
cytotoxicity [47,71]. 
Spongidepsin  has been isolated from the marine sponge Spongia sp. Its structure contains   
9-hydroxy-2,4,7-trimethyltetradeca-14-ynoic acid and N-methylphenylalanine residues joined in a   
13-membered ring. Spongidepsin shows cytotoxic activity against J774.A1, WEHI-164 and HEK-293 Mar. Drugs 2010, 8                
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cancer cell lines with an IC50 in the sub-micromolar range [72]. Assignment of absolute 
stereochemistry and total synthesis were reported [73–75]. 
Nine new cyclodepsipeptides, homophymines, B–E and A1–E1, were isolated from the sponge 
Homophymia sp. The new structures, featuring new polyketide-derived end groups, display very potent 
cytotoxic activity with IC50-values in the nM range against a panel of human cancer cell lines [76]. A 
comparison of their activity against different tumor cell lines showed moderate selectivity toward 
human prostate (PC3) and ovarian (OV3) carcinoma. When their resistant counterpart cell lines were 
compared (MCF7/MCF7R, HCT116/HCT15, HL60/HL60R), no significant differences were 
observed, indicating that overexpression of P-gp (MDR1, ABCB1) did not affect the intracellular 
accumulation of homophymines suggesting that they are not substrates for the efflux pump. In terms of 
the structure-activity relationship, homophymines A1–E1, featuring the 4-amino-6-carbamoyl-2,3-
dihydroxyhexanoic acid residue, exert stronger potency, when compared to the corresponding A–E 
compounds in which the same residue is in its carboxy form. However, the lack of an effect of 
homophymines on caspases 3 and 7 activation indicates that homophymines display a toxic rather than 
antiproliferative activity [76]. 
3.2. Mode of action  
In contrast to microtubules, which have been targeted successfully with anti-tumor drugs such as 
taxol-like compounds and the vinca alkaloids, very few actin-targeting drugs have been characterized. 
To date, no actin targeting drugs have been used in clinical trials due to their severe cytotoxicity. One 
reason for this cytotoxicity is that drugs such as cytochalasins and latrunculins disrupt actin 
microfilaments in both non-tumor and tumor cells [67,77]. However, geodiamolide H and 
jasplakinolide might be promising candidates. Agents that inhibit Rho GTPases, such as Rac1, may 
likely be less toxic. Rac1, Cdc42, and Rho A are well known for their role in the regulation of the actin 
cytoskeleton [78,79]. 
3.2.1. Actin polymerization  
Jasplakinolide, which is a representative member of the cyclodepsipeptide family, is a potent 
inducer of actin polymerization in vitro [80]. Actin is a ubiquitous eukaryotic cytoskeletal protein, 
critical for many aspects of cell activity. In addition to maintaining cell morphology, it is required for 
cell motility, cell division, and intracellular transport [81]. Cellular actin rapidly alternates between 
two forms, monomeric G-actin (globular) and polymeric F-actin (fibrous). The dynamics of the   
G-actin to F-actin transition may be critical to many cellular functions including cell division. 
Interestingly, jasplakinolide has a much greater effect on Mg
2+-actin than on Ca
2+-actin. Competitive 
binding studies suggest that jasplakinolide binds to F-actin competitively with phalloidin with a 
dissociation constant of approximately 15 nM. It was suggested that jasplakinolide might exert its 
cytotoxic effect in vivo by inducing actin polymerization and/or inhibiting depolymerization of   
actin filaments [80]. 
The effect of jasplakinolide on the in vitro proliferation and differentiation of leukemic cell lines 
and blast cells from three acute myeloid leukemia patients was comparable to that of cytosine 
arabinoside. At micromolar concentrations, jasplakinolide suppressed both primary colony formation Mar. Drugs 2010, 8                
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in agar and the recovery of clonogenic cells from suspension cultures in a dose-dependent manner in 
the investigated cell lines as well as in fresh blasts (Table 3). In addition, jasplakinolide caused the  
up-regulation of CD14 and CD11 and down-regulation of CD34 antigens. These results indicate that 
jasplakinolide significantly inhibits the self-renewing capacity of leukemic progenitors [82]. 
Table 3. Anti-tumor activity of sponge-derived cyclodepsipeptides. 
Cyclodepsipeptide  Marine sponge  Cell line  Growth inhibitory 
concentration (IC50) 
Ref. 
Arenastatin A 
(cryptophycin –24) 
 
 
diethylamine 
analog  
Dysidea arenaria  KB 3-1 
 
 
 
S180 
5 pg/mL 
 
 
 
0.18 ng/mL 
[92]  
[93] 
[94] 
 
[95] 
Geodiamolides  Geodia sp.  
and  
Geodia 
corticostylifera 
 
 
sea urchin eggs; 
T47D and MCF7 
 
Hs578T  
 
 
≈100–600 nM 
≈20–115 nM 
 
120 nM 
[86] 
 
[87] 
[87] 
 
[88] 
Homophymines  Homophymia sp.  PC3, OV3, MCF7/MCF7R, 
HCT116/HCT15, HL60/HL60R 
2–100 nM  [76] 
Jasplakinolide 
(jaspamide) 
Jaspis sp.  
and  
Hemiastrella minor 
HL-60  
 
 
 
 
Jurkat T cells, EL-4, SP-2/0, J774.1 
100 nM 
50 nM 
100 nM 
100 nM 
 
2 µg/mL 
[83] 
[89] 
[91] 
[96] 
 
[90] 
Spongidepsin  Spongia sp.  J774.A1  
WEHI-164  
HEK-293 
0.56 µM 
0.42 µM 
0.66 µM 
[72] 
Theopapuamides  Geodia barretti 
and  
Siliquariaspongia 
mirabilis 
CEM-TART HCT-116  
 
 
HCT-116 
0.5 µM 
0.9 μM 
 
Theop. A: 2.1 μg/mL 
Theop. B: 4.0 μg/mL 
Theop. C: 2.1 μg/mL 
[55] 
 
 
[50] 
Exposure of promyelocytic HL-60 cells and human monocytes to jasplakinolide causes a dramatic 
reorganization of actin from a typical fibrous network to focal aggregates. HL-60 cells exposed to 50 
or 100 nM jasplakinolide exhibit a reduced proliferation rate (Table 3). In addition, 100 nM 
jasplakinolide induces the maturation of HL-60 cells to a granulocyte monocyte lineage. It upregulates 
the expression of the differentiation markers CD16 and CD14 B. Jasplakinolide also causes the 
aggregation of F-actin in HL-60 cells and human monocytes. Cultured human monocytes contract and Mar. Drugs 2010, 8                
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adopt round shapes after treatment with jasplakinolide, and a dose-dependent increase in both total 
actin and de novo synthesized portions of the soluble actin is observed in HL-60 cells. Jasplakinolide 
disrupts the actin cytoskeleton of normal and malignant mammalian cells with no significant effects on 
phagocytic activity [83]. 
Jasplakinolide paradoxically stabilizes actin filaments in vitro, but in vivo it can disrupt actin 
filaments and induce polymerization of monomeric actin into amorphous masses. Jasplakinolide 
markedly enhances the rate of actin filament nucleation. This increase corresponds to a change in the 
size of actin oligomers that can nucleate filamentous growth from four to approximately three 
subunits, which is mechanistically consistent with the presence of the jasplakinolide-binding site at the 
interface of three actin subunits. Because jasplakinolide simultaneously decreases the amount of 
sequestered actin and augments nucleation, the enhancement of polymerization by jasplakinolide is 
amplified in the presence of actin-monomer sequestering proteins such as thymosin β4. Overall, the 
kinetic parameters in vitro define the mechanism by which jasplakinolide induces polymerization of 
monomeric actin in vivo. The expected consequences of jasplakinolide are consistent with the 
experimental observations and include de novo nucleation resulting in disordered polymeric actin and 
insufficient monomeric actin to allow for remodelling of stress fibers [84]. 
Actin filaments in suspension-cultured Nicotiana tabacum Bright Yellow 2 cells are disrupted by 
jasplakinolide in a concentration- and time-dependent manner. When cells are treated with a moderate 
concentration (150 nM) of jasplakinolide, cortical actin filaments are disrupted preferentially, and actin 
aggregates in the perinuclear region. At concentrations higher than 400 nM and exposure times longer 
than 30 min, actin filaments in the cell disappear completely. The effect of jasplakinolide on the actin 
cytoskeleton is reversible even at high concentrations. Although actin filaments disappear in certain 
cytoplasmic areas in jasplakinolide-treated cells, jasplakinolide is generally accepted as an actin-
polymerizing and actin-stabilizing drug [85]. 
Geodiamolides A and B present antifungal activity, while geodiamolide H is active against a 
number of cancer cell lines [86]. The anti-proliferative effects of geodiamolides A, B, H and I were 
investigated against sea urchin eggs (Lytechinus variegatus), and T47D and MCF7 human breast 
cancer cells lines (Table 3). The anti-proliferative activity against breast cancer cells occurred through 
the disorganization of actin filaments, while microtubule organization was not affected. Normal cell 
lines, however, did not show cytoskeletal alterations after treatment with the peptides, which 
underscores the biomedical potential of such compounds. Small structural alterations in geodiamolides 
largely affect the rank order of potency in each cell line, indicating different cellular sensitivities 
depending on the phenotype of the cell. Differences in peptide potencies are associated with an amino 
acid substitution (alanine versus β-tyrosine) or with the presence of bromide or iodide in the phenol 
ring of the N-methyltyrosine moiety [87]. 
Geodiamolide H selectively interferes with actin cytoskeleton of tumor cells (Hs578T, T47D, 
MCF7), while having no effect on normal cells (MCF 10A, primary culture human fibroblasts, BRL3A 
rat liver epithelial cells) [87,88]. This cyclodepsipeptide significantly decreases migration and invasion 
of Hs578T cells due to modifications in the actin cytoskeleton. As no effect on metalloproteinases has 
been found, it is suggested that actin is the major target of geodiamolide H in Hs578T cells, and 
impacts cell motility [88]. Mar. Drugs 2010, 8                
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3.2.2. Polyploidization  
A previous study demonstrated that jasplakinolide at 50 nM exhibits antiproliferative activity and 
increases CD4 and CD14 surface expression. The exposed cells became multinuclear, and the size and 
the number of nuclei of the cells increased in a time-dependent manner. In addition, an increased 
number of metaphase chromosomes were observed. Analysis of the DNA content of HL-60 cells 
revealed a significant increase in the percentage of cells with increased DNA content. These findings 
indicate that the jasplakinolide induces polyploidization [89]. 
3.2.3. Apoptosis  
Jasplakinolide induces cell death via apoptosis. Jasplakinolide is thought to induce apoptotic cell 
death through a caspase-3-like protease-dependent pathway. In addition, it has been demonstrated that 
various transformed cell lines, such as human leukemia Jurkat T cells, murine T lymphoma EL-4 cells, 
murine myeloma SP-2/0 cells, murine macrophage-like J774.1 cells and murine fibroblast L cells, are 
more sensitive to jasplakinolide-induced apoptosis than normal, non-transformed cells such as murine 
thymocytes and spleen T cells [90]. 
Jasplakinolide-induced loss of viability by programmed cell death in the HL-60 human 
promyelocytic leukemia cell line is accompanied by neutral endopeptidase/CD10 expression on the 
surface of the apoptotic cells. HL-60 cells normally do not express detectable amounts of neutral 
endopeptidase/CD10 on their surface or in the cytoplasm. This implies an association between 
apoptosis induction and CD10/neutral endopeptidase expression in myeloid cell lines. Moreover, in the 
promonocytic U937 and mature monocytic THP-1 cell lines, jasplakinolide induced apoptosis but not 
CD10 expression. In HL-60 cells, CD10 expression was partially, but not totally, blocked by a broad-
spectrum caspase inhibitor. Therefore, these results suggest that programmed cell death induced by 
jasplakinolide occurs via caspase-dependent and -independent pathways [91]. 
Homophymins display very potent cytotoxic activity with IC50-values in the nM range against a 
panel of human cancer cell lines [76]. However, the lack of an effect of homophymines on caspases 3 
and 7 activation indicates that homophymines display a toxic rather than antiproliferative activities. 
3.3. Jasplakinolide and arenastatin A analogs as mechanistic probes  
The mechanism of action of depsipeptide-based actin-targeting compounds is quite unclear in terms 
of the molecular aspects of their interaction with a biological target. It is difficult to explain the similar 
effects of these metabolites on actin in the absence of a receptor map and additional structural details. 
Previous investigations on jasplakinolide have indicated that the two structural elements of the 
molecule, the tripeptidic portion and the polyketide fragment, play a cooperative role in creating the 
bioactive shape of the compound [97,98]. In fact, it seems that the tripeptide moiety, in the 
macrocycle, is forced to adopt a preferential β-turn conformation, indicating that the polyketide 
fragment plays a decisive role in generating geometric constrains and inducing a selective 
conformation [68]. Synthesis and biological evaluation of modified jasplakinolide analogs were 
performed to obtain additional information on the potential pharmacophoric core of the target 
molecule. Although the biological profile of jasplakinolide is established, many mechanistic details are Mar. Drugs 2010, 8                
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still missing in terms of molecular target identification. For this reason, the natural metabolite was 
synthetically modified with a β-amino acid in the cyclopeptide backbone, similar to the parent 
compound [99]. However, the extreme simplified polyketide moiety, which was necessary to allow 
more synthetic accessibility of analogs, was detrimental to biological activity [68]. 
Arenastatin A (Figure 3) has an identical structure to cryptophycin-24, which was isolated from the 
cyanobacterium  Nostoc sp. [100]. The cyclodepsipeptide was shown to have extremely potent 
cytotoxic activity (IC50 = 5 pg/mL) against KB 3-1 cells. Cytotoxicity is caused by inhibition of 
microtubule assembly through binding to the rhizoxin/maytansine site on tubulin [93,94]. However, 
arestatin A was found to exhibit only marginal in vivo anti-tumor activity after intravenous 
administration due to rapid metabolism of the 15,20-ester linkage in arenastatin A. To overcome this 
biological instability, a 15,20-triamide analog was synthesized, in which the labile ester function is 
replaced by an amide moiety. This analog was found to show sufficient stability in serum and 
moderate levels of cytotoxicity (IC50 = 6 ng/mL). However, it was almost insoluble in polar solvents, 
thus it could not be applied for in vivo biological evaluation [101]. Therefore, a series of arenastatin A 
analogs was synthesized [95,102], and two tertiary amine analogs with polar diethylamine and 
piperazine moieties on the phenyl ring were found to be the most potent cytotoxic compounds   
(IC50 = 0.18 and 1.5 ng/mL, respectively) with good solubility and stability. The in vivo anti-tumor 
activity of the intraperitoneally applied diethylamine analog was tested in subcutaneously implanted 
murine sarcoma S180 cells (Table 3). The diethylamine analog inhibited the growth of the tumor at a 
dose of 1 mg/kg with comparable efficacy to that of 5 mg/kg doxorubicin, without signs of acute 
toxicity [95].  
Figure 3. Structure of arenastatin. 
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4. Cyclodepsipeptides as Pharmacological Tools  
4.1. Tools for studying actin organization and dynamics  
Jasplakinolide is a potentially useful pharmacological tool for the study of actin organization and 
dynamics in living cells, since it induces actin polymerization in vitro and, unlike phalloidin, is 
membrane permeable. Jasplakinolide continues to be employed in studies investigating the role of the 
actin cytoskeleton in various cell processes. For example, jasplakinolide induces the formation of the 
acrosomal process in a protozoan parasite [103]. Stabilization of actin filaments by jasplakinolide 
arrests oocyte maturation, cortical granule exocytosis, sperm incorporation, cone resorption, and cell 
cycle progression during fertilization in mice [104]. When treated with jasplakinolide, morphological 
changes in the Golgi complex are blocked, suggesting that they are correlated with actin cytoskeleton Mar. Drugs 2010, 8                
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rearrangements [105]. Jasplakinolide’s inhibition of actin filament disassembly was employed to 
reveal the role of actin depolymerization in lamellipodial protrusion [106]. 
Participation of the actin cytoskeleton in the transduction of proliferative signals has been 
established through the use of compounds that disrupt the cytoskeleton. To address the possibility that 
actin also participates in the transduction of apoptotic signals, the response of the murine interleukin 2 
(IL-2)-dependent T cell line CTLL-20 to treatment with jasplakinolide upon IL-2 deprivation was 
studied. Treatment of CTLL-20 cells with jasplakinolide, in the presence or absence of recombinant 
human IL-2, altered actin morphology. Jasplakinolide was not toxic to CTLL-20 cells, nor was 
apoptosis induced in the presence of exogenous recombinant human IL-2. However, actin stabilization 
at the time of IL-2 deprivation enhanced apoptosis by changing the kinetics of apoptotic commitment. 
This effect of jasplakinolide correlated with its ability to stabilize polymerized actin, as treatment with 
a synthetic analog of jasplakinolide with a greatly reduced ability to bind actin, jasplakinolide B, did 
not enhance apoptosis. This enhancement occurred upstream of the induction of caspase-3-like activity 
and could be inhibited by the overexpression of the anti-apoptotic protein Bcl-xL. These data suggest 
that the actin cytoskeleton plays an active role in modulating lymphocyte apoptosis induced by 
cytokine deprivation [107]. 
Jasplakinolide markedly influences the morphogenetic process in the green alga Micrasterias when 
used at concentrations higher than 3 µM. Upon treatment, the development of Micrasterias is inhibited 
or strongly retarded, malformations occur, and large vacuoles are formed. At the ultrastructural level, 
dense, abnormal accumulations of filamentous structures have been found, indicating actin filament 
polymerization  in situ. Moreover, the displacement of organelles and aggregates of endoplasmic 
reticulum cisternae were observed, but microtubule arrangement and microtubule-dependent processes 
remained undisturbed. Cells allowed to recover from jasplakinolide treatment continued their growth, 
but showed severe changes in the cell pattern and displacement of organelles, suggesting that even 
after removal of the drug, some basic features for the morphogenetic process remained altered. Taken 
together, jasplakinolide is a powerful tool for investigations into actin-dependent processes [108].  
Whereas the actin cytoskeleton is a key component involved in cell migration, agents targeting actin 
dynamics have been investigated. Consequently, valuable in vitro pharmacological tools are needed to 
selectively identify agents that target actin dynamics. In response to the absence of any standardized 
process, Hayot et al. [67] developed a multi-assay strategy for screening actin-affecting drugs with 
anti-migratory potentials. For validation, they used the cancer cell lines MCF7 and A549, and the three 
actin-affecting drugs cytochalasin D, latrunculin A, and jasplakinolide. The effects of these drugs on 
the kinetics of actin polymerization were quantified in tubes by spectrofluorimetry, and on the 
dynamics of actin within whole cells by fluorescence microscopy. Using quantitative 
videomicroscopy, they investigated the effects of the drugs on cell motility. Finally, the combined drug 
effects on cell motility and cell growth were evaluated by means of a scratch-wound assay. While the 
results showed concordant drug-induced effects on actin polymerization in vitro in test tubes and 
within whole cells, the whole cell assay was more sensitive than the tube assay. The inhibition of actin 
polymerization induced by cytochalasin D was paralleled by a decrease in cell motility for both cell 
types. However, jasplakinolide significantly enhanced the locomotion of A549 cells, while it 
significantly inhibited the movement of MCF-7 cells. All these effects were confirmed by the scratch-
wound assay, except for the effects of jasplakinolide on MCF-7 cell motility. These events were later Mar. Drugs 2010, 8                
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compensated by additional effect that occurred during wound recolonization, possibly through effects 
on the cell growth features. Therefore, the use of multi-assays with different levels of sophistication 
and biological relevance is recommended for the screening of new actin-affecting drugs with 
potentially anti-migratory effects [67]. 
4.2. Tools for studying the role of inhibition of Na
+/Ca
2+ exchange 
In cardiac sarcolemmal vesicles, callipeltin A induces a powerful (IC50 = 0.85 µM) and selective 
inhibition of the Na
+/Ca
2+ exchanger. In electrically driven guinea-pig atria, callipeltin A causes a 
positive inotropic effect, which is accompanied by a rise in resting tension at high concentrations. 
Thus, the positive inotropic effect is linked to the inhibition of the Na
+/Ca
2+ exchanger, making 
callipeltin A a useful tool for studying the role of the cardiac Na
+/Ca
2+ exchanger in physiological and 
pathological conditions [70]. Furthermore, it was reported that the effect of callipeltin A on cardiac 
and vascular preparations is linked to sodium ionophoric action [109].  
4.3. Tools for studying cAMP-dependent transepithelial Cl
- secretion  
Previous studies have shown that cAMP-dependent transepithelial Cl
- secretion in the intestinal cell 
line T84 is reduced upon treatment with phalloidin, an effect that is partly attributed to inhibition of 
basolateral Na
+-K
+-2Cl
- cotransport. However, secretory responses are preserved in cells treated with 
the microfilament disrupter cytochalasin D. Jasplakinolide inhibits cAMP-dependent secretion and 
Na
+-K
+-2Cl
- cotransport. Latrunculin A, which sequesters G-actin monomers, profoundly alters the 
distribution of F-actin and reduces basal transepithelial resistance with minimal effect on secretion. 
Cytochalasin D, but not latrunculin A, activates Na
+-K
+-2Cl
- cotransport. These observations have 
provided further evidence that vectorial ion transport is influenced by the cytoskeleton and support a 
model in which disassembly of F-actin by specific pharmacological agents or in response to secretory 
agonists favors activation of Na
+-K
+-2Cl
- cotransport [110].  
5. Conclusions 
Most of the cyclodepsipeptides that are currently evaluated in clinical trials are used in refractory 
cancer therapy. They include kahalalide F and aplidin (plitidepsin), which were isolated from mollusks 
or green algae, and tunicate, respectively. They have shown promising results in phase I and II clinical 
trials, especially when administered in combination with other chemotherapeutic agents. At present, 
the biological activity of cyclodepsipeptides from marine sponges remains to be validated in animal 
studies, and clinical trials are lacking. In cell-based assays, interesting mechanisms of the compounds 
have been found such as the inhibition of HIV-virus entry (e.g., mirabamides and papuamide A) and 
actin polymerization (in particular jasplakinolide). Progress has also been made in structure-activity 
relationship studies, but only small quantities of these natural compounds can be isolated and purified, 
and this has made the in vivo validation of these compounds difficult. For instance, didemnin B, a 
cyclodepsipeptide isolated from a tunicate, is an example of an in vitro effective compound that failed 
to show anticancer activity at non-toxic concentrations in humans. Therefore, structural determination, 
structure-activity relationships and the elaboration of large-scale total synthesis of marine sponge Mar. Drugs 2010, 8                
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derived compounds are required for pharmacodynamic, pharmacokinetic and toxicological evaluation 
of marine sponge-derived cyclodepsipetides. However, despite the lack of therapeutic validation of 
these compounds, they remain valuable molecular probes for investigating new signaling pathways. 
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